Case Report | Open | Published:
Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report
BMC Research Notesvolume 6, Article number: 508 (2013)
Although a number of studies have reported acquired drug resistance due to administration of epidermal growth factor receptor antibody inhibitors, the underlying causes of this phenomenon remain unclear.
Here we report a case of a 75-year-old man with liver metastasis at 3 years after a successful transverse colectomy to treat KRAS wild-type colorectal cancer. While initial administration of epidermal growth factor receptor inhibitors proved effective, continued use of the same treatment resulted in new peritoneal seeding. An acquired KRAS mutation was found in a resected tissue specimen from one such area. This mutation, possibly caused by administration of epidermal growth factor receptor inhibitors, appears to have conferred drug resistance.
The present findings suggest that administration of epidermal growth factor receptor inhibitors results in an acquired KRAS mutation that confers drug resistance.
A better understanding of the mechanisms underlying changes in KRAS in response to epidermal growth factor receptor (EGFR) inhibitors might contribute to improvement in the treatment of colorectal cancer (CRC). Here we report a case of an acquired KRAS mutation that appears to have conferred drug resistance following administration of cetuximab and discuss it in light of the recent literature.
The patient was a 75-year-old man with a history of hypertension, cerebrovascular disease, and adjustment disorder, but no known allergies. The patient’s father also had a history of colon cancer.
In December 2004, the patient underwent a transverse colectomy for transverse colon cancer (T3 N1 M0 stage IIIa) at another hospital. Due to adjustment disorder, the patient was closely monitored, but no adjuvant chemotherapy administered.
In March 2006, a colonoscopy revealed that the cancer had anastemotic recurrence, and in April 2006 the patient underwent a subtotal colectomy and anastomosis of the sigmoid colon and ileum.
In April 2007, the patient’s tumor markers were elevated and positron emission tomography-computed tomography (PET-CT) revealed metastasis to the liver and para-aortic lymph nodes. Chemotherapy with 5-fluorouracil/leucovorin/ oxaliplatin (FOLFOX4) was started as first-line treatment in May 2007. After 15 courses of treatment, the patient exhibited signs of progressive disease. Bevacizumab could not be administered, however, as the patient also had cerebrovascular disease.
In February 2008, chemotherapy with 5-fluorouracil/ leucovorin/irinotecan (FOLFIRI) was started as second-line treatment. After 16 courses of treatment, imaging revealed an increase in liver metastasis, and the patient was referred to our hospital.
At the time of admission, the patient measured 186.5 cm in height, weighed 80.1 kg, had a Body Mass Index (BMI) of 23, and a Performance Status (PS) of 0. Normal heart sounds and breathing were noted, without abdominal abnormalities being observed, there was no leg edema, and the patient had grade1 peripheral neuropathy. Blood tests showed a normal blood count, and blood levels of carcinoembryonic antigen (CEA) and carbohydrate antigen (CA)19-9 at 88.8 ng/mL and 312.2 U/mL, respectively. Chest and abdominal X-rays, as well as an electrocardiogram, also revealed no abnormalities. An abdominal CT showed shadows on his liver at S4 and S8 (Figure 1). A PET-CT scan (1/29) showed liver metastases at S8, S4 and S3. The resected primary tumor tested positive for EGFR and showed the presence of wild-type KRAS. EGFR was analyzed by immunohistochemistry.
KRAS genotyping using tumor samples was analyzed by Luminex® assay.
The analytical sensitivity of the Luminex® assay is 0.4% (GENOSEARCH HS KRAS).
After admission, chemotherapy with irinotecan and cetuximab (CPT-11 + C-mab) was started as third-line treatment in January 2009. After 13 courses of treatment, blood CEA and CA19-9 levels dropped to 14.3 ng/mL and 16.8 U/mL, respectively, and liver metastases showed a reduction (Figure 2), indicating a partial response. A left hepatectomy was performed in September 2009, and tumor markers dropped to normal levels. The resected tumor specimen showed the presence of wild-type KRAS.
In October 2009, postoperative chemotherapy was commenced with CPT-11 + C-mab. Six courses (courses 14–19) of treatment were completed, after which the patient only came in for follow-up without continuing chemotherapy.
In July 2010, the patient exhibited peritoneal dissemination and lung metastasis (S2,S4,S5,S8), and treatment with CPT-11 + C-mab was recommenced. After 18 courses of treatment (courses 20–37), no change was observed in lung metastases, and no new areas of metastasis were detected, indicating stable disease (SD).
In August 2011, the patient underwent lung metastasis resection. In October 2011, new areas of lung metastasis were found, while the primary tumor remained unchanged (SD). Treatment with CPT-11 + C-mab was started again (courses 38–48). Courses 39–41 and 45–48 consisted of only cetuximab. The lung metastases remained unchanged (SD) after 11 courses of treatment.
In May 2012, emergency gastric bypass surgery was performed for an obstruction in the ileum due to seeding in the patient’s duodenum (Figure 3). A KRAS mutation was detected in the resected seeding tissue.
At present, only palliative treatment is being administered as the patient has completed standard treatment.
While the patient’s resected tumors from both 2004 and 2009 showed the presence of wild-type KRAS, and the administration of cetuximab for 2 years and 4 months proved effective, the resected seeding tissue from his intestinal obstruction was found to have a KRAS mutation. Hence, it can be possibly concluded that administration of EGFR inhibitors resulted in an acquired KRAS mutation that conferred drug resistance.
In 1988, Vogelstein et al. proposed a multi-stage theory of carcinogenesis known as the adenoma-carcinoma sequence, in which colorectal cancer arises due to mutations that activate multiple oncogenes and inactivate tumor suppressor genes, which then accumulate on the epithelium of a normal colon, forming adenomas. KRAS mutations were proposed to be driver mutations in colorectal carcinogenesis . Earlier studies have noted similar KRAS mutations in both the primary tumor and metastases in more than 90% of patients with CRC or lung cancer [2, 3]. Moreover, in addition to these two studies, another report also noted a small number of cases of KRAS mutations in metastases arising from wild-type KRAS primary tumors . Colorectal tumors with wild-type KRAS are often sensitive to EGFR blockade . The mechanism underlying an acquired resistance to EGFR inhibitors, however, remains largely unknown. The previously reported lower concordance levels of KRAS between the primary tumor and metastases are likely due to bias arising from false-negative results in underpowered studies and the correct evaluation of the amount of tumor tissue in the sample, or the sensitivity of the testing method used . Previously published data showed that a considerable fraction of colorectal lymph node metastases do not resemble the primary tumor in terms of KRAS mutation status . Heterogeneity in lymph node metastases could explain this discordance in a small number of cases, but its main mechanism is unknown. Misale et al. also reported that use of anti-EGFR drugs for metastatic CRC contributed to acquisition of a KRAS mutation . There are two possible explanations for the discordant results for KRAS: heterogeneity of KRAS status within the primary tumor [8–10], or clonal selection during the process of metastasis . Another clinical study identified wild-type KRAS in 10 patients with acquired resistance to anti-EGFR therapy. Meanwhile, a KRAS G13D mutation was identified in 4 further cases, and the simultaneous presence of G12D and G13D mutations in one. In 6 patients for whom sufficient pre-treatment tumor samples were available for high-coverage 454 sequence analyses or beads, emulsion, amplification and magnetics, KRAS mutations were found to be absent. Tumors from a further 8 patients treated with cytotoxic chemotherapy but not previously exposed to anti-EGFR therapies were also analyzed by 454 deep sequencing. In all 8 cases, the analyses identified no evidence of a KRAS mutation. These results indicate an association between treatment with anti-EGFR antibodies, not cytotoxic chemotherapy, and acquisition of KRAS mutations . The mechanism of resistance to anti-EGFR therapy has recently been clarified. Montagut et al. reported an acquired EGFR ectodomain mutation (S492R) that prevented cetuximab binding, thus conferring resistance to this drug. The cells with this mutation, however, retained binding to panitumumab, which inhibited their growth. In that study, 2 of 10 patients acquired this mutation after cetuximab treatment. One patient with cetuximab resistance and harboring the S492R mutation responded to treatment with panitumumab. This indicates that panitumumab may be effective in patients with the S492R mutation after failure of cetuximab. A re-biopsy would be needed before commencing treatment with a molecularly targeted drug, however [10, 11]. In further study, we aim to analyze KRAS status by using circulating tumor cells, which play a core role in liquid biopsy. Resistant cells remained sensitive to combinatorial inhibition of EGFR and mitogen-activated protein-kinase (MEK), and mutated KRAS alleles were detected in the blood of cetuximab-treated patients as early as 10 months before radiographic documentation of disease progression .
In summary, there is a growing body of evidence to suggest that EGFR inhibitor-induced KRAS mutations that associates with tumor recurrence. The results of the present study suggest that such mutations could be identified non-invasively months before disease progression became evident radiographically, and that early initiation of a MEK inhibitor would be a rational strategy for delaying or reversing drug resistance. If such strategies were employed, this might allow ineffective drugs to be terminated earlier and more effective treatment strategies pursued.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Positron emission tomography-computed-tomograpy
Body mass index
Beads, emulsion, amplification and magnetics
Circulating tumor cells.
Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med. 1998, 319: 525-532.
Han CB, Li F, Ma JT, Zou HW: Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review. Cancer Invest. 2012, 30 (10): 741-747. 10.3109/07357907.2012.732159.
Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Shibuya H, Eshima K: Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. Dis Colon Rectum. 2011, 54 (9): 1170-1178. 10.1097/DCR.0b013e31821d37a3.
Knijn N, Mekenkamp LJ, Klomp M, Vink-Börger ME, Tol J, Teerenstra S, Meijer JW, Tebar M, Riemersma S, Van Krieken JH, Punt CJ, Nagtegaal ID: KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer. 2011, 104 (6): 1020-1026. 10.1038/bjc.2011.26.
Ciardiello F, Tortora G: EGFR antagonists in cancer treatment. N Engl J Med. 2008, 358: 1160-1174. 10.1056/NEJMra0707704.
Bouchahda M, Karaboué A, Saffroy R, Innominato P, Gorden L, Guettier C, Adam R, Lévi F: Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. Cancer Chemotherapy Pharmacol. 2010, 66 (3): 605-609. 10.1007/s00280-010-1298-9.
Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A: Emergence of KRAS mutation and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012, 486 (7404): 532-536.
Diaz LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B: The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012, 486 (7404): 537-540.
Li Z, Jin K, Lan H, Teng L: Heterogeneity in primary colorectal cancer and its corresponding metastases: a potential reason of EGFR-targeted therapy failure?. Hepatogastroenterology. 2011, 58 (106): 411-416.
Bardelli A, Jänne PA: The road to resistance : EGFR mutation and cetuximab. Nature medicine. 2012, 18: 199-200. 10.1038/nm.2646.
Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S, Tsai SP, Minoche A, Seshagiri S, Serrano S, Himmelbauer H, Bellmunt J, Rovira A, Settleman J, Bosch F, Albanell J: Identification of a mutation in the extracellular domain of the epidermal growth facter receptor conferring cetuximab resistance in colorectal cancer. Nature medicine. 2012, 18 (2): 221-223. 10.1038/nm.2609.
The authors declare that they have no competing interests.
The original manuscript was written by HO. HO and MS and ES and MS and NM performed chemotherapy for mCRC. AS and MU and TY performed a left hepatectomy, MM performed a lung resection. All authors contributed to drafting and editing the manuscript. All authors read and approved the final manuscript.